engleski

Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b

Patient self-reporting of adverse events is alternative approach and could provide valuable information. Data obtained from patients could be sometimes different from physicians but they are complementary, each providing clinically meaningful information. In this article we present a patient who has been suffering from multiple sclerosis, treated by Interferon Beta -1b (IFNB-1b) over the past 10 years. This self reported case of liposarcoma is suspected to be related to the concurrent treatment with IFNB-1b opens numerous questions. On the basis of data available yet, we cannot conclude that the use of IFNB - 1b is related with the occurrence of malign disease in this case, but our effort to communicate these concerns with the patient resulted in continuation of our co-operation with the patient and his willingness to continue with the same immunomodulatory agent. Relationship with patients based on mutual appreciation is crucial for compliance and prevention of future relapses of MS.

Liposarcoma ; Multiple sclerosis ; Interferon beta

nije evidentirano